Obsidian Therapeutics
  • About Us
    • Overview
    • Our Vision
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • Overview
    • Our Pipeline
    • cytoDRiVE® PLATFORM
    • Publications
    • Partners
  • Our Lead Clinical Program
    • Overview
    • For Patients
    • Expanded Access Policy
    • OBX-115
  • News
  • Join Our Team
    • Overview
    • Our Culture
    • Testimonials
    • Benefits
    • Job Postings
  • Contact

News

Back to News
Next
April 28, 2025

Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 28, 2025 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of an abstract with preclinical data from their cytoDRiVE® platform for poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2025.

Obsidian will present novel applications of its cytoDRiVE platform, demonstrating the breadth and versatility of their regulation technology. To date, cytoDRiVE technology has been used to successfully regulate the timing and level of several different classes of therapeutic protein via fusion to drug-responsive domains (DRDs).1 In OBX-115, Obsidian’s lead clinical TIL program which has demonstrated promising activity in patients with ICI-resistant advanced melanoma2, this technology enables regulation of membrane-bound IL15 using the small-molecule drug acetazolamide.

The poster for abstract AMA30 expands beyond the direct DRD-fusion approach leveraged to-date, providing proof-of-concept for a novel approach whereby regulation of an artificial transcription factor is used to enable gene-ON and gene-OFF states with ligand binding. This approach unlocks numerous additional applications for cytoDRiVE, including the ability to regulate secreted proteins and expression of mRNA or siRNA. These capabilities become important in the context of gene and cell therapies where precise and variable genetic control is needed to manage disease, and where repeat dosing of other complex biologics is challenging.

Details of the poster presentation are as follows:

  • Title: Drug-responsive domains coupled with cognate small-molecule ligands drive synthetic gene-ON or -OFF circuits to regulate expression of therapeutic proteins (Abstract AMA30)
  • Presenting Author: Michael Gallo (Obsidian Therapeutics)
  • Poster: Tuesday, May 13, 6:00-7:30pm CT
  • Abstract: AMA30

1 Inniss et. al. Commun Biol 2025

2 Chesney, ASCO 2025

 

About OBX-115

Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613).

 

About Obsidian Therapeutics

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.

 

Inquiries:

Jeffrey Trigilio

Chief Financial Officer

jtrigilio@obsidiantx.com

Back to News
Obsidian Therapeutics
  • About Us
  • Our Science
  • Our Lead Clinical Program
  • News
  • Join Our Team
  • Contact

Privacy // Terms of Use
© 2025 Obsidian Therapeutics, Inc. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Our Pipeline Job Postings
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. By continuing to navigate our website, you consent to the use of cookies, our privacy policy and terms of use.
Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT